In November 2013 and January 2014, two studies were published reporting increased cardiovascular risks in men on testosterone replacement therapy (TRT). These studies triggered a flurry of concern in the general public and medical profession, including the FDA. When investigated by multiple sexual medicine societies, both studies were found to have significant flaws in methodology that challenged their conclusions. In addition, there is a body of scientific literature supporting that testosterone deficiency may increase cardiovascular risk and be associated with increased risk of other comorbidities, including obesity and type 2 diabetes. There is also preliminary evidence that, in some hypogonadal men, TRT can improve glucose metabolism and lower overall risk of cardiovascular events. In order to resolve the situation, there needs to be a long-term, randomized, placebo-controlled clinical trial to better assess cardiovascular risk in hypogonadal men undergoing TRT. At The Billups Center, we take the time to educate men about the potential risks and benefits of testosterone deficiency and TRT. While there is no final consensus on cardiovascular risk associated with TRT, we feel that with proper education, evaluation, monitoring and follow up, TRT is an appropriate treatment for many men. Each man is assessed on an individual basis and followed with a treatment plan that is personalized for his medical status.